Table 3.
Ongoing comparative drugs trials in thyroid cancer.
| Type of thyroid cancer | Intervention | Comparison | Expected end | Current status | Identifier |
|---|---|---|---|---|---|
| DTC* | Sorafenib | Placebo | Dec 2013 | Ongoing, not recruiting | NCT00984282 |
| DTC | Lenvatinib | Placebo | Jul 2013 | Active, not recruiting | NCT01321554 |
| DTC | Cediranib | Cediranib and lenalidomide | Sep 2013 | Recruiting | NCT01208051 |
| DTC, MTC** | Everolimus pasireotide | Everolimus or pasireotide | Jun 2014 | Recruiting | NCT01270321 |
*DTC: differentiated thyroid cancer.
**MTC: medullary thyroid cancer.